The estimated Net Worth of James Edgemond is at least $7.71 Milion dollars as of 9 September 2024. Mr. Edgemond owns over 8,332 units of United Therapeutics Corp stock worth over $1,494,848 and over the last 10 years he sold UTHR stock worth over $0. In addition, he makes $6,216,460 as Chief Financial Officer a Treasurer at United Therapeutics Corp.
Sign up
Mr. Edgemond UTHR stock SEC Form 4 insiders trading
James has made over 6 trades of the United Therapeutics Corp stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 8,332 units of UTHR stock worth $991,341 on 9 September 2024.
The largest trade he's ever made was exercising 40,160 units of United Therapeutics Corp stock on 15 May 2024 worth over $6,558,128. On average, James trades about 4,494 units every 37 days since 2015. As of 9 September 2024 he still owns at least 4,318 units of United Therapeutics Corp stock.
You can see the complete history of Mr. Edgemond stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Edgemond biography
James C. Edgemond serves as Chief Financial Officer, Treasurer of the Company. Mr. Edgemond was promoted to Chief Financial Officer and Treasurer in March 2015. Prior to joining United Therapeutics, he was Vice President, Corporate Controller and Treasurer of Clark Construction Group from 2008 through January 2013. He also served in a variety of roles at The Corporate Executive Board Company from 1998 to 2008, serving as Executive Director, Finance from 2005 to 2008. He began his career as a public accountant at KPMG Peat Marwick LLP, from 1990 through 1998, where he served in a variety of roles, including as a Senior Manager prior to his departure.
What is the salary of James Edgemond?
As the Chief Financial Officer a Treasurer of United Therapeutics Corp, the total compensation of James Edgemond at United Therapeutics Corp is $6,216,460. There are 3 executives at United Therapeutics Corp getting paid more, with Martine Rothblatt having the highest compensation of $15,627,500.
How old is James Edgemond?
James Edgemond is 52, he's been the Chief Financial Officer a Treasurer of United Therapeutics Corp since 2015. There are 18 older and 2 younger executives at United Therapeutics Corp. The oldest executive at United Therapeutics Corp is Louis Sullivan, 86, who is the Independent Director.
What's James Edgemond's mailing address?
James's mailing address filed with the SEC is C/O UNITED THERAPEUTICS CORPORATION, 1000 SPRING STREET, SILVER SPRING, MD, 20910.
Insiders trading at United Therapeutics Corp
Over the last 20 years, insiders at United Therapeutics Corp have traded over $68,910,395 worth of United Therapeutics Corp stock and bought 229,703 units worth $13,655,671 . The most active insiders traders include Martine A Rothblatt, David Zaccardelli a Roger Jeffs. On average, United Therapeutics Corp executives and independent directors trade stock every 3 days with the average trade being worth of $2,310,818. The most recent stock trade was executed by James Edgemond on 9 September 2024, trading 8,332 units of UTHR stock currently worth $991,341.
What does United Therapeutics Corp do?
united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians
What does United Therapeutics Corp's logo look like?
Complete history of Mr. Edgemond stock trades at United Therapeutics Corp
United Therapeutics Corp executives and stock owners
United Therapeutics Corp executives and other stock owners filed with the SEC include:
-
Martine Rothblatt,
Chairman of the Board, Chief Executive Officer -
Michael Benkowitz,
President, Chief Operating Officer -
Paul Mahon,
Executive Vice President, General Counsel, Corporate Secretary -
James Edgemond,
Chief Financial Officer, Treasurer -
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.,
Founder, Chairman & CEO -
Dr. Martine A. Rothblatt,
Founder, Chairman & CEO -
Michael I. Benkowitz,
Pres & COO -
Paul A. Mahon,
Exec. VP, Gen. Counsel & Corp. Sec. -
Paul A. Mahon J.D.,
Exec. VP, Gen. Counsel & Corp. Sec. -
James C. Edgemond,
CFO & Treasurer -
Christopher Patusky,
Lead Independent Vice Chairman of the Board -
Christopher Causey,
Independent Director -
Richard Giltner,
Independent Director -
Louis Sullivan,
Independent Director -
Tommy Thompson,
Independent Director -
Nilda Mesa,
Independent Director -
Judy Olian,
Independent Director -
Katherine Klein,
Independent Director -
Raymond Kurzweil,
Independent Director -
Raymond Dwek,
Independent Director -
Linda Maxwell,
Director -
Dewey Steadman C.F.A.,
Head of Investor Relations -
Leigh Peterson,
VP of Product Devel. -
Gil Golden,
Sr. VP & Chief Medical Officer -
Patrick Poisson,
Exec. VP of Technical Operations -
Kevin T. Gray,
Sr. VP of Strategic Operations & Logistics -
Holly Hobson,
Associate VP of HR -
Dewey Steadman C.F.A., CFA,
Head of Investor Relations -
Jan Malcolm,
-
Ray Kurzweil,
-
Roger Jeffs,
President & COO -
Fred T Hadeed,
EVP & CFO -
David Zaccardelli,
EVP & Chief Operating Officer -
John Maxim Ferrari,
CFO & Treasurer -
R Paul Gray,
Director -
Lilly & Co Eli,
Director, Chairman and CEO